The hypoxia-selective cytotoxin NLCQ-1 (NSC 709257) controls metastatic disease when used as an adjuvant to radiotherapy
Lunt, S J, Cawthorne, C, Ali, M, Telfer, B A, Babur, M, Smigova, A, Julyan, P J, Price, P M, Stratford, I J, Bloomer, W D, Papadopoulou, M V, Williams, K J
Published in British journal of cancer (13.07.2010)
Published in British journal of cancer (13.07.2010)
Get full text
Journal Article
The hypoxia-selective cytotoxin NLCQ-I (NSC 709257) controls metastatic disease when used as an adjuvant to radiotherapy
LUNT, S. J, CAWTHORNE, C, PAPADOPOULOU, M. V, WILLIAMS, K. J, ALI, M, TELFER, B. A, BABUR, M, SMIGOVA, A, JULYAN, P. J, PRICE, P. M, STRATFORD, I. J, BLOOMER, W. D
Published in British journal of cancer (2010)
Get full text
Published in British journal of cancer (2010)
Journal Article
Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy
Silk, Jonathan D, Hermans, Ian F, Gileadi, Uzi, Chong, Tsung Wen, Shepherd, Dawn, Salio, Mariolina, Mathew, Bini, Schmidt, Richard R, Lunt, Sarah Jane, Williams, Kaye J, Stratford, Ian J, Harris, Adrian L, Cerundolo, Vincenzo
Published in The Journal of clinical investigation (01.12.2004)
Published in The Journal of clinical investigation (01.12.2004)
Get full text
Journal Article
Effects of the vascular disrupting agent ZD6126 on interstitial fluid pressure and cell survival in tumors
SKLIARENKO, Julia V, LUNT, Sarah Jane, GORDON, Maggie L, VITKIN, Alex, MILOSEVIC, Michael, HILL, Richard P
Published in Cancer research (Chicago, Ill.) (15.02.2006)
Published in Cancer research (Chicago, Ill.) (15.02.2006)
Get full text
Journal Article